2013 GIBH
2010-2013 Product Development/Portfolio Manager, R&D, Biotherapeutics, Molecular Devices
2009-2010 Senior Scientist, R&D, Drug Discovery, Leica ???????
2008-2009 Non-Clinical Research Fellow , Royal Hallamshire Hospital
2005-2008 Doctoral Research Student, PhD,? Medical School, Sheffield
2002-2005 Bachelor's Degree, Bsci, Biochemistry, University of Sheffield
2000-2002 A-level, Barnsley CollegehiPSCs application development for HCS / HTS drug screening and clinical application
Cell Signalling in Innate Immunity and Inflammation for cardiovascular application
2012 - Co-Investigator/Applicant , BBSRC, ?(grant No. BB/J009687) industry application grant: Defining TILRR regulation of distinct IL-1RI responses using systems biology – ￡1,2M
2010 - R&D Exceptional Science Award,
?
ZHANG X, MONTAGUT PINO G, SHEPHARD F, KISS-TOTH E and QWARNSTROM EE, 2012. Distinct control of MyD88-dependent and AKT-regulated responses by the IL-1R1 co-receptor, TILRR. Journal of Biological Chemistry. 287(15), 12348-52 Cover of Journal issue April 6th, 2012
?
ZHANG, XIAO, SHEPHARD, FREYA, KIM, HONG B, PALMER, IAN R, MCHARG, SELINA, FOWLER, GREGORY J S, O'NEILL, LUKE A J, KISS-TOTH, ENDRE and QWARNSTROM, EVA E, 2010. TILRR, a novel IL-1RI co-receptor, potentiates MyD88 recruitment to control Ras-dependent amplification of NF-kappaB. The Journal of biological chemistry. 285(10), 7222-32
?
Monica Neilan, Xiao Zhang, Sheila Francis, Eva E Qwarnstrom, 2010. BAS/BSCR51 Control of vascular cell inflammatory responses through TILRR, an interleukin 1 co-receptor. Heart. 10; 96(17):e27. ?
?
M Neilan, X Zhang, T Steiner, J Boyle, S Francis, D Haskard, E Qwarnstrom, 2012. TILRR Functional Mutants Selectively Inhibit Inflammatory and Anti-Apoptotic Responses. Heart. 12; 98(10):e6
?
